H.R. 8857: Next Generation Medicines Act of 2026

This bill, titled the Next Generation Medicines Act of 2026, aims to modify the rules surrounding a specific type of drug known as engineered cyclic peptides within the U.S. Drug Price Negotiation Program. Here are the main points covered in the bill:

Definitions and Key Changes

• The bill proposes to extend the exclusivity period for engineered cyclic peptides from 7 years to 11 years. This means that the makers of these drugs will have an extended period during which they are the only ones allowed to sell them without competition from generic versions.
• An engineered cyclic peptide is defined within the bill as a type of polymer primarily made of amino acids, which has specific characteristics:
  • It contains at least one cyclic structure created through various methods of cyclization.
  • It includes no more than 40 amino acids.
  • It was developed using a genetically encoded library screening method and is not derived from natural sources.
  • It must be administered orally, inhaled, or self-administered in some other way.

Effective Date

The changes proposed in the bill would be effective for lists published under the relevant section of the Social Security Act on or after the bill's enactment date.

Impact on Drug Pricing

This amendment would likely influence the pricing and market availability of engineered cyclic peptides, as extending exclusivity could impact how quickly generics enter the market and how much competition there is on pricing after the exclusivity period ends.

Relevant Companies

• AMGN (Amgen Inc.) - As a company involved in biotechnology and pharmaceuticals, Amgen may be affected as it develops and markets engineered cyclic peptides.
• REGN (Regeneron Pharmaceuticals) - This company focuses on drug development, including engineered therapies that could qualify under the new classification.
• VRNA (Verona Pharma) - They develop innovative therapeutics and could be significantly impacted by changes in pricing regulations for their products.
• ALNY (Alnylam Pharmaceuticals) - A biotech firm that may also have products categorized as engineered cyclic peptides, making them subject to the new legislative changes.